NEUTRA CORP |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
Financials (USD)
| Sales 2022 | 0.09 | Sales 2023 | 0.07 | Capitalization | 1.2M |
|---|---|---|---|---|---|
| Net income 2022 | - | Net income 2023 | - | EV / Sales 2022 | 26,053,405 x |
| Net Debt 2022 | 241K | Net Debt 2023 | 54.5K | EV / Sales 2023 | 18,402,377 x |
| P/E ratio 2022 |
-2.61
x | P/E ratio 2023 |
-1.94
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.31% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Sydney Jim
CEO | Chief Executive Officer | 39 | 13-05-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sydney Jim
CEO | Chief Executive Officer | 39 | 13-05-01 |
Neutra Corp. is an early-stage research and development company. The Company is engaged in marketing and participating in the nutraceutical space by bringing products derived from all natural and organic origins. The Company plans to research and bring new technology to the Nutraceutical space. The Company is primarily focused on participating in the medical cannabis market, which is a nutraceutical sub-market. It intends to entrust the manufacturing to a nutraceutical contractor to private label all of its products and to sell them under its brand. It primarily sells hemp-derived products, including products containing delta-8-THC and other cannabinoids. Its subsidiaries include Diamond Anvil Designs, LLC, Deity Corporation and Vivis Corporation.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +24.17% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.45% | 233B | |
| +6.04% | 201B | |
| -10.51% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
